sessions bio-europe...panelist: regina hodits - managing partner, wellington partners life sciences...

Anatomy of a deal: Amgen and Neuvolution

On demandBusiness Development Track

During the summer of 2019 Amgen acquiredNuevolution, a leading small molecule discoveryplatform, now operating as Amgen ResearchCopenhagen. With the acquisition of Nuevolution,Amgen obtained world-class DNA-encoded librarycapability and screening power to add uniquecapabilities to Amgen’s small molecule drug discoveryefforts, complementing the already broad researchdiscovery expertise in human monoclonal antibodiesand BiTE® molecules. Margaret Chu-Moyer and TonBerkien will discuss why Amgen was looking for smallmolecule research capabilities, how the transactioncame about and how the integration so far hasdelivered on the promise.

Participants

Host: Lucie Ellis - Executive Editor, In Vivo, InformaPharma Intelligence

Guest: Ton Berkien - Director, Transactions, BusinessDevelopment, Amgen

Guest: Margaret Chu-Moyer - VP, Research and Headof Chemistry, Characterization & Technology, Amgen

Emergence of novel therapeutic modalities inneurodegeneration

On demandTherapeutic Track

Participants

Moderator: Christian Jung - Partner, DementiaDiscovery Fund

Panelist: Sarah Cole - VP, Research and Development,TranSINE Therapeutics

Panelist: Tim Luker - VP, Emerging Technology &Innovation, Corporate Business Development, Eli Lilly &Company

Panelist: Rogier Rooswinkel - Principal, Forbion

Panelist: Beth Shafer - Sr. Director, CEI, R&D BusinessDevelopment, Takeda Pharmaceuticals

What a pandemic has taught us about digitalhealth

On demandBiotech Ecosystem

Digital health is by no means new, but it has taken apandemic to see a massive uptick in adoption of theway we deliver therapies and healthcare. This sessionwill explore how COVID accelerated the digital trendand insights on how digital health will impact thefuture of care delivery and patient treatment.

Participants

Moderator: Jessica Shull - European Lead, DigitalTherapeutics Alliance

Panelist: Regina Hodits - Managing Partner, WellingtonPartners Life Sciences

Panelist: Douglas Lee - VP, Head Digital and DataScience, Business Development & Licensing, Bayer

Panelist: Austin Speier - Chief Strategy Officer, ClickTherapeutics

Ride the new wave in Korea’s pharmaceuticalindustry

On demandSpotlight

This session describes the current landscape ofimmuno-oncology and regenerative medicinedevelopment in Korea and introduces the clinical trialinfrastructure that supports these developments.

Participants

Moderator: Deok Cheol Kwon - President, KHIDI

Panelist: Lauren Lee - VP, Hanmi Pharma

Panelist: Antonio Lee - Managing Director, Medipost

Panelist: In Jin Jang - Director, Seoul NationalUniversity Clinical Trials Center

Discovery of new species by high-throughputcultivation of anaerobic bacteria isolated fromhuman gut samples

On demandMicrobiome Therapeutics

Participants

Speaker: Julian Riba - CSO, Cytena

In conversation with Husseini Manji


Participants

Host: Paul Tunnah - Founder, pharmaphorum andChief Content Officer and UK MD, Healthware Group

Guest: Husseini Manji - Global Head, Science forMinds, Johnson & Johnson

Changing the game for external innovation andpartnering at Bayer, a conversation with Dr.Marianne De Backer


In today’s innovation ecosystem, the ability to forgestrong partnerships is key to pharmaceuticalcompanies in their pursuit of finding better or newtreatment options for patients. On the occasion of BIO-Europe, Paul Tunnah speaks with Dr. Marianne DeBacker, Bayer’s executive responsible for strategy andexternal innovation. She shares insights about her firstyear at Bayer and her strategic vision for taking thecompany’s engagement with current and potentialpartners to new heights. Adaptive and agile approachto deals and related decision-making are consideredkey. Dr. De Backer passionately elaborates on thepurpose of leveraging breakthrough science andpartnerships in ultimately making a difference forpatients.

Participants

Host: Paul Tunnah - Founder, pharmaphorum andChief Content Officer and UK MD, Healthware Group

Guest: Marianne De Backer - Member ofPharmaceuticals Executive Committee and ExecutiveVP and Head of Strategy, Business Development &Licensing, Bayer AG

Genetically engineered microbial medicines(GEMMs) for the treatment of chronic diseases


• Developing a suite of synthetic biology tools forengineering highly abundant gut commensals

• Establishing an exclusive niche through rarecarbohydrate utilization enables robust andcontrollable gut colonization of engineered strains

• The company’s lead program to treat hyperoxaluriais nearing first-in-human studies

Participants

Speaker: Lane Weaver - Head, Business Development,Novome Biotechnologies

SESSIONSON DEMAND SESSIONS -

BIO-EuropeOctober 26–29, 2020

Delivered DigitallyEuropean Standard Time

+49 89 2388 756 0 informaconnect.com/bioeurope/ [email protected]

The future of biotech investment


Participants

Moderator: Hubert Birner - Managing Partner, TVMCapital

Panelist: Johnston Erwin - VP, Corporate BusinessDevelopment, Eli Lilly and Company

Panelist: Olivier Litzka - Partner, Andera Partners

Panelist: Amy Schulman - Managing Partner, PolarisPartners

Panelist: Otello Stampacchia - Managing Director,Omega Funds

Next directions in oncology


Participants

Moderator: Luc Marengère - Managing Partner, TVMCapital

Panelist: Khatereh Ahmadi - Executive Director,Business Development and Licensing, MSD

Panelist: Aaron Chen - Senior Director, GlobalBusiness Development & Licensing, Oncology, Bayer

Panelist: Brendan Luu - VP, Head of OncologyBusiness Development, Merck KGaA

Panelist: Alain Thibault - Principal, TVM Capital

Collaboration Close up: Global GrassrootsInnovation at Boehringer Ingelheim


Participants

Host: Kevin Grogan - Managing Editor, Europe, PharmaIntelligence

Guest: Maria Antonietta Impagnatiello - Manager,Global Business Development and Licensing, SPOncology, Boehringer Ingelheim

Guest: Ioannis Sapountzis - Corporate SVP, BusinessDevelopment and Licensing, Boehringer Ingelheim

Guest: Mengtao Xiao - Senior Manager, BusinessDevelopment and Licensing, Boehringer Ingelheim

Navigating Korea investment and ecosystem toconnect global bio-pharma

On demandSpotlight

• Introduction to Korea Investment Ecosystem forBio-Pharma Sector

• Korea’s Overseas Financial Investment: Readinessto Invest in Global Promising Bio-PharmaCompanies

• Korea’s Infrastructure Investment: Move-inAttractiveness for Global Promising Bio-PharmaInstitutions

• Korea’s Capital Market: Outstanding IPOopportunity for Global Promising Bio-PharmaInstitutions

• Korea’s R&D Investment: Co-R&D efforts betweenand among Leading Bio-Pharma Companies

• How Korea Investment Ecosystem will Impact theGlobal Bio-Pharma Industry

Participants

Moderator: Paul Yun - CEO, Ildong Pharmaceuticalsand Chairman, KPBMA Global Affairs Committee

Panelist: Mahn Soon Hwang - Senior ManagingDirector, Korea Investment Partners (KIP)

Panelist: Se Joon Kim - Director General of InvestmentInducement, Incheon Free Economic Zone (IFEZ)

Panelist: Min Suk Lee - Senior Manager, KoreaExchange (KRX)

Panelist: Kevin Kyung Hwa Huh - CEO, KoreaInnovative Medicines Consortium (KIMCo)

Small molecule mining of human surrogatemicrobiome for therapeutics


• Technological breakthroughs now allow obtainingnatural microbiome and interrogating the actualhidden chemistry along with the genomics

• Direct and indirect support for therapeuticopportunities emerging from natural environmentalmicrobiome habitats is evidenced by drugs on themarket or candidates in the pipeline and genomicand metabolic pathway overlap to various humanmicrobiome

Participants

Speaker: Ross Youngs - CEO, Biosortia

Effective and efficient clinical trial strategies


Participants

Moderator: Richie Pfeiffer - Senior Product Director,Innovation, Covance

Panelist: Geert-Jan Mulder - Managing Partner,Forbion

Panelist: Bray Patrick-Lake - Director, StrategicPartnerships, Evidation Health

Formulating an R&D vision at Servier


Claude Bertrand talks with Andrew McConaghie aboutthe reasons behind Servier's revitalization of their R&Dstrategy, the evolution of their therapeutic area focusand the unique perspective and culture that resultsfrom operating as a foundation.

Participants

Host: Andrew McConaghie - Senior Writer, Scrip

Guest: Claude Bertrand - SVP, Head of R&D, Servier

The repercussions of manufacturingrequirements on cell and gene therapy deals


Participants

Moderator: Jessica Carmen - Consultant, PullanConsulting

Panelist: Brian Bronk - Head of Business Developmentand Licensing, Rare diseases, Neurosciences andInnovative Technologies Group, Sanofi

Panelist: Bernd Muehlenweg - SVP, Innovate StrategicInitiatives, Evotec

Panelist: Jens Vogel - SVP, Global Head of Biotech,Bayer Pharmaceuticals





Regulatory considerations for microbiomebased therapeutics


As microbiome science has developed over the pastfew years, new perspectives have appeared in terms ofhealth technology development. While translation froma therapeutic candidate into potential treatment isalready ongoing, a wide diversity is observed in termsof product type and status (e.g. prebiotics, probiotics,postbiotics; but also food, grafts, LBPs, GMOs…). Todate, there is no consolidated regulatory frameworkapplicable encompassing all microbiome healthtechnologies. As often when a new category ofproduct emerges, whenever a dedicated regulatoryframework seems to be required, collaborationbetween developers and regulators is key to design thecorresponding technical and regulatory requirementsthat will support scientifically sound and pragmaticdevelopments of safe and efficient therapeutics.Following the initial effort from national regulatoryAuthorities and multi-stakeholders initiatives fromscientific institutions and industry, a clear need isidentified for a more harmonized and globallyrecognized guidance as well as compatible regulatoryprocesses for the microbiome product developmentand approval.

Participants

Moderator: Francois Gianelli - Director, CMC & Quality,Voisin Consulting Life Sciences

Speaker: Hervé Affagard - CEO, MaaT Pharma

Speaker: Paul Carlson - Principal Investigator, CBER atFDA

Speaker: Susan Stewart - Chief Regulatory Officer,Kaleido Biosciences

Strategic collaboration with clients and valueenhancing partners: the why, what and how


Federico Pollano discusses the key elements inRentschler's approach to partnerships, highlightingnew collaborations that have been made during thepandemic and Rentschler's focus on developingsolutions in the rare disease space.

Participants

Host: Lucie Ellis - Executive Editor, In Vivo, InformaPharma Intelligence

Guest: Federico Pollano - Senior VP, BusinessDevelopment, Rentschler Biopharma SE

Rare diseases, patient data, and collaboration


From identifying unmet needs to post-market follow-ups, patient data plays a major role in the developmentof therapeutics and curative treatments for rarediseases. This session will discuss the connectionsand collaborations that facilitate the effective use ofpatient data in developing drugs for rare diseases andthe ways these collaboration models may impact thelifespan of treatments long after they are on themarket.

Participants

Moderator: Craig Martin - President, ChiefEngagement Officer, Rithm Health

Panelist: Mette Kirstine Agger - Managing Partner,Lundbeckfonden Ventures

Panelist: Nick Meade - Director of Policy, GeneticAlliance UK

Panelist: Anthony Philippakis - Chief Data Officer,Broad Institute

Panelist: Ian Winburn - Global Medical Team Lead,Haemophilia, Endocrine and IEM, Rare Diseases, Pfizer

Korea’s Rising Bio Stars

On demandSpotlight

This session features interviews with five of Korea'smost exciting new companies including

• ILIAS BIO• Aribio• REDNVIA• Immunomax• NEXEL

Case study: Crowdsourcing to examinevariation in microbiome standards


This session is a case study covering data collectionand sequencing standardization.

Complex multispecies bacterial communities – ismade more challenging by the high levels of diversity.Protocol steps, including extraction, purification, librarypreparation, and sequencing of genetic data fromthese communities may inadvertently introduce biasinto the results. Through the Mosaic onlinemicrobiome analysis platform, we provided standard,identical microbiome samples to communityvolunteers, who extracted and sequenced the geneticmaterial using their normal protocols. We collected thesequencing results and protocol data and analyzedthem using a consistent bioinformatics pipeline toexamine variation. We found that, while differentextractions from the same samples cluster together,we observe significant shifts in the resulting organismabundance profiles; samples processed with the same,or similar, protocols showed greater similarity thanidentical biological samples processed using differentprotocol methods. These results suggest that protocolchoices may introduce bias into microbiomeexperiments and must be carefully selected andmaintained to ensure that comparisons of microbiomeresults are not skewed by underlying protocolchanges.

Participants

Speaker: Sam Westreich - Microbiome Specialist andBioinformatician, DNA Nexus

Partnering for impact: The importance ofaccessing external innovation for Novartis


James Bradner, NIBR President, talks about theimportance of partnering and how Novartis accessesexternal innovation to bring transformative medicinesto patients

Participants

Guest: James Bradner - President, Novartis Institutesfor BioMedical Research (NIBR)





New tools to conquer chronic kidney disease


Participants

Moderator: Joseph Haas - Senior Writer, PharmaIntelligence

Panelist: Lars Erwig - VP of CVM Innovation, Johnson& Johnson Innovation

Panelist: Anne Fortier - Director, Discovery Biology,Vertex Pharmaceuticals

Panelist: Andrew King - Head of Renal Discovery andTranslational Medicine, Chinook Therapeutics

Panelist: Olivier Radresa - VP, Nephrology, Evotec

In conversation with Sofinnova Partners'Graziano Seghezzi


Participants

Host: Mike Ward - Global Head of Thought Leadership,DRG, part of Clarivate

Guest: Graziano Seghezzi - Partner, SofinnovaPartners

Patient-first discovery of bacterial biomarkersand live bacterial therapeutics for cancerimmunotherapy


• New best-in-class study into how the gutmicrobiome impacts response to immunecheckpoint inhibitors in advanced melanoma

• Precision mapping of this studyusing Microbiotica’s platform has identified a pre-treatment microbiome signature highly predictiveof response to anti-PD1 therapy across 4independent melanoma studies

• A live bacterial therapeutic is being developedbased on a consortium of strains associated withresponse to enhance the efficacy of anti-PD1therapy in melanoma

• Analysis indicates microbiome associated withresponse varies between indications

Participants

Speaker: Mat Robinson - VP, Translational Biology,Microbiotica

How the right CDMO can support yourproduct’s path to clinic


Companies developing new biologics have highexpectations and the smallest details can determinelong-term success. With the right service portfolio aCDMO can help streamline the path to clinic withcustomized and experienced based solutions tosupport pharmaceutical and biotech companies frompreclinical development all the way through successfulmarket launch.

Moderator: Deborah Gravelle, Content MarketingCoordinator, EBD Group

Interviewee: John Moore, Director of Global ClinicalBusiness Development, Vetter Pharma International

Watch Interview

Watch on YouTube

AGC Biologics Capabilities and theintroduction of Cell & Gene Therapy


Participants

Speaker: Luca Alberici , AGC Biologics

Speaker: Bryson Kneller - VP Process Development,AGC Biologics

Machine Learning (ML) methods for biomarkeridentification for microbiome therapeutics,diagnostics and prognostics


• Understanding the power of ML in microbiomeresearch

• How can microbiome ML development aid theidentification of new biomarkers to novelmicrobiome-based therapeutics

• Good methodology for result’s analysis that can beused for comparison across studies

Participants

Speaker: Marcus Claesson - Principal Investigator,University College Cork

From research to market: developing a biotechproject in Wallonia


In this fireside chat, Eric Halioua from Beligium-basedPDC Line Pharma, discusses how the regionalecosystem has supported the company's developmenton an international scale.

Participants

Host: Andrew McConaghie - Senior Writer, Scrip

Guest: Eric Halioua - CEO, PDC Line Pharma

How to develop immunoregulatorypharmabiotics


• How to select the right microorganism to treateither hyper-immune disorders or cancer

• What are the effector molecules mediating theunique function of selected microorganism?

• Preclinical data of the effector molecules whichrecapitulate the whole bacteria

Participants

Speaker: Sin-Hyeog Im - Professor at POSTECH andCEO & Founder, ImmunoBiome Inc.

Health Equity: Addressing Health DisparitiesDuring Therapeutic Development


In order to improve health outcomes for diversepopulations, it’s essential to begin by eliminatinghealth disparities. With the spread of a pandemic thatdisproportionately affects communities of color andcontinued systemic inequality, BIO has launched theBIOEquality Agenda with a primary goal of promotinghealth equity. Learn from biopharma executives,clinicians, and patients about pathways to ensure thatclinical trials are representative of patient populationsand companies ensure access to prevention andtreatment of diseases including COVID-19.

Participants

Moderator: Cartier Esham - Executive VP, EmergingCompanies, Biotechnology Innovation Organization(BIO)

Paneilst: Barbara Bierer - Faculty Director, Professor ofMedicine, Harvard Medical School

Panelist: John Dwyer - President, Global Alzheimer’sPlatform Foundation





https://partneringone.informaconnect.com/event/687/profile/user/584/company/1

https://partneringone.informaconnect.com/event/687/company/859

https://glsr.live/GQ9Vdnv

https://youtu.be/eRTbb-D01NM

How COVID-19 is Bending the Curve onVaccine Development and ManufacturingNorms


Catalent announced its acquisition of the Anagni, Italysite from Bristol-Myers Squibb in June 2019 toenhance its late-stage and commercial capabilities forbiologics, sterile injectables and oral solid doseproducts in Europe. As the COVID-19 virus began tospread into a global pandemic, the site quickly pivotedits efforts to support manufacturing hundreds ofmillions of doses of COVID-19 vaccine candidates inEurope.

In this interview, hear Mario Gargiulo, Catalent’s RegionPresident, Biologics, Europe describe the acceleratedtimelines and activities required to produce COVID-19vaccine and therapeutic candidates in Anagni and ourother global biologic sites.

Participants

Host: Dan Stanton - Editor and Founder, BioprocessInsider, part of Informa Life Sciences' BioProcessInternational

Guest: Mario Gargiulo - Region President, Europe,Catalent Biologics

Using customized phage cocktail mixture toeradicate bacteria in chronic diseases


• Fusobacterium nucleatum bacteria eradication totreat colorectal cancer

• Using advanced synthetic biology to engineerphages

• Optimizing phage cocktail selection in vitro and invivo for best activity

Participants

Speaker: Assaf Oron - Chief Business Officer, BiomX

Partnering in a pandemic world: inconversation with Martin Crook and Brian Cook


Participants

Host: Linda Pullan - President, Pullan Consulting

Guest: Brian Cook - Executive Director, OncologyTransactions, Bristol-Myers Squibb

Guest: Martin Crook - Executive Director, OncologySearch and Evaluation, Bristol-Myers Squibb

Connecting clinic and commercial: Biopharmamanunfacturing


Join this panel about how a new level of visibility forthe biopharma manufacturing sector has changedrelationships, investments, and capabilities. Thediscussion will explore not only the rapid adjustmentsmade in response to the urgent concerns regardingvaccine production but also the transformations madeto accommodate new modalities and considerationsaround global manufacturing capacity.

Participants

Moderator: Anthony Davies - Founder and CEO, DarkHorse Consulting Group

Panelist: José Castillo - CTO, Univercells

Panelist: Charles Christy - Head of CommercialSolutions, Ibex Solutions, Lonza

Symbiotic Drugs: Pharmaceutical control ofthe gut microbiome


• Small-molecule, non-antibiotic drugs thatselectively target injury-causing bacterial activity

• Modulating xenobiotic metabolism by gutmicrobiota to improve the therapeutic window ofcancer, pain and immunosuppressant medications

Participants

Speaker: Ward Peterson - CEO and President,Symberix

Expect more with Siegfried as your preferredpartner


Siegfried is your partner of choice in terms ofdevelopment and manufacturing for your oral & sterileproducts. From our drug product network, currentlyconsisting of a highly skilled team of more than 800employees spread over four sites in Europe & US, wecan offer you development, clinical & commercialsupply services. Furthermore, two additional sites inSpain will be integrated into Siegfried's Drug ProductNetwork beginning 2021. We can suit your needsalong the several product stages, ranging from small-scale clinical up to large commercial scalemanufacturing.

Moderator: Karina Marocco, Program Manager,Campaign Marketing, EBD Group

Interviewee: Laura de Miguel, PhD, Senior ManagerBusiness Development Drug, Siegfried AG

Interviewee: Till Röhrich, PhD, Head R&D Oral DrugProduct, Siegfried AG

Interviewee: Mario Vlasic, Senior Manager BusinessDevelopment Drug Product, Siegfried AG

Interviewee: Sasa Kolaric, Manager Product &Business Development Drug Product, Siegfried AG

Interviewee: Olaf Wegener, Head R&D Sterile DrugProduct, Siegfried AG

Watch Interview

Watch on YouTube





https://partneringone.informaconnect.com/event/687/profile/user/584/company/1






https://glsr.live/2pdiucl

https://youtu.be/XzWIv-hsS1U

Designing scale up and manufacturingprocesses for microbiome therapeutics – endto end manufacturing issues – manufacturingand analytical challenges


Recent researches demonstrated thatmicrobiota can sustain, promote and restore health.Novel therapeutic strategies promote health aretherefore increasingly aiming at strains or consortia ofstrict anaerobic bacteria known as Next-generationProbiotics or live biotherapeutic products (LBP). Theproduction of individual commercial probiotic strainssuch as Lactobacilli or Bifidobacteria is currentlycarried-out at large scale using batch fermentations. Incontrast, production of strains of human microbiomeorigin has only been seldom investigated.

Lot of challenges remains today, and technology islacking for implementation of human LBPmanufacturing at scale. Indeed, most of theseorganisms are strict anaerobes, highly sensitive toenvironmental stresses encountered during processes,with complex, often unknown nutrient requirements,and limited or variable growth. This presentation willfocus on innovative strategies to support themanufacturing of human microbiome related strains(single strains and/ or consortia) as well as on thepractical and regulatory constraints associated withthe CMC chapter.

Industrial manufacturing strategies are a critical stepand a key challenge towards the commercialization ofLBP which need to be addressed in the most efficientway.

Participants

Speaker: Alain Sourabié - Science Technology andInnovation Director, Procelys by Lesaffre

Cross-Border Partnering between Europe, US &China


China, with a large patient population, has become theworld’s second-largest pharmaceutical market. With arapidly increasing emphasis on innovative healthcare,Chinese investors and pharmaceutical companies areactively looking for global opportunities. This sessionwill discuss cross-border collaborations betweenEurope, US & China, and opportunities and challengesfor assets in different clinical trial stages to enterChina.

Participants

Moderator: Echo Hindle-Yang - Founder and CEO, MSQVentures

Panelist: Robert Narquizian - Director, BioBaselConsulting and ChinaBio Capital

Panelist: Joan Shen - CEO, I-Mab Biopharma

Panelist: Shawn Singh - CEO, VistaGen

Panelist: Ed Zhang - Venture Partner, Hillhouse CapitalManagement

Commercialization opportunities within thehuman microbiome industry


• Therapeutics reaching the market: an overviewfrom America and Canada

• What are the stages of microbiome therapeuticscommercialization?

• Perceptions and misconceptions from the buyer atthe end of the chain

• How can the industry interface with on-goingresearch that findings from the lab can betransferred to the clinic?

Participants

Panelist: Jean-Francois Denault - CEO, Impacts CA

In conversation with Jeetendra Vaghjiani


Participants

Host: Julianna LeMieux - Science Writer, GEN: GeneticEngineering and Biotechnology New

Guest: Jeetendra Vaghjiani - Director of CommercialDevelopment, Mammalian and Microbial Development,Lonza

Microbiome industry breakthroughs – drugdevelopment plans


Participants

Speaker: Todd Krueger - Chief Executive Officer andPresident, AOBiome

Linking immunity and cancer to humanmicrobiome


• How can cancer patients improve their outcomeswith microbiome-based therapeutics?

• Oncology (MRx0518)

Participants

Speaker: Alex Stevenson - Chief Scientific Officer, 4dPharma

Woman’s health care and vaginal microbiota


• Phase II clinical trial in bacterial vaginosis

• Clinical trial results

• What does the future of vaginal microbiomeholds?

Participants

Speaker: Peter Lee - Founder and Executive Chairman,Osel In

Strain-Level Profiling of the Gut Microbiome -A Novel Therapeutic Strategy to Prevent orTreat Sepsis


• How does sepsis change the gut microbiome inways that affect health and behavior?

• What are the advantages of longitudinal strain-levelprofiling of the gut microbiome?

Participants

Speaker: Candice Brown - Principal Investigator, WestVirginia University





Building patent portfolios protectingmicrobiome therapeutics: Recent guidance andbest strategies


A presentation from J A Kemp will cover recentguidance and best strategies for building patentportfolios that protect microbiome therapeutics in arobust manner and thus provide valuable commercialassets. Bacterial products are far more complex thansmall molecule drugs and antibodies and so theyrequire a tailored approach. It is also not yet settledhow bacteria are best defined in patent claims, or whatscope claims limited to bacterial strains might have.The presentation will review recent patent cases thatprovide some much-needed guidance and will discusscreative patent drafting strategies utilising input fromtechnical and commercial teams to generate strongand flexible patent portfolios that fully supportdevelopment of microbiome therapeutics.

Participants

Speaker: Ian MacLeod - Partner, Patent Attorney, J. A.Kemp

Specializing and investing in the microbiomespaces


• What is driving an increased interest in themicrobiome industry?

• What are investors looking for?

• What are the latest investment trends?

• What can you do to stand out as a microbiomecompany when forging new partnerships?

Participants

Moderator: Denise Kelly - Investment Advisor,Seventure Partners





TIME BIOTECH ECOSYSTEM BUSINESS DEVELOPMENT TRACK MICROBIOME THERAPEUTICS SPOTLIGHT THERAPEUTIC TRACK

00:00 On demand - What a pandemic hastaught us about digital health

On demand - Collaboration Close up:Global Grassroots Innovation atBoehringer Ingelheim

On demand - Anatomy of a deal: Am-gen and Neuvolution

On demand - In conversation withHusseini Manji

On demand - Changing the game forexternal innovation and partnering atBayer, a conversation with Dr. Mari-anne De Backer

On demand - The future of biotech in-vestment

On demand - Discovery of newspecies by high-throughput cultiva-tion of anaerobic bacteria isolatedfrom human gut samples

On demand - Genetically engineeredmicrobial medicines (GEMMs) for thetreatment of chronic diseases

On demand - Ride the new wave inKorea’s pharmaceutical industry

On demand - Emergence of noveltherapeutic modalities in neurode-generation

On demand - Next directions in oncol-ogy

01:00 On demand - Effective and efficientclinical trial strategies

On demand - Rare diseases, patientdata, and collaboration

On demand - Formulating an R&D vi-sion at Servier

On demand - Strategic collaborationwith clients and value enhancing part-ners: the why, what and how

On demand - Small molecule miningof human surrogate microbiome fortherapeutics

On demand - Regulatory considera-tions for microbiome based therapeu-tics

On demand - Navigating Korea invest-ment and ecosystem to connect glob-al bio-pharma

On demand - The repercussions ofmanufacturing requirements on celland gene therapy deals

02:00 On demand - AGC Biologics Capabili-ties and the introduction of Cell &Gene Therapy

On demand - Partnering for impact:The importance of accessing exter-nal innovation for Novartis

On demand - In conversation withSofinnova Partners' GrazianoSeghezzi

On demand - How the right CDMOcan support your product’s path toclinic

On demand - Case study: Crowd-sourcing to examine variation in mi-crobiome standards

On demand - Patient-first discovery ofbacterial biomarkers and live bacteri-al therapeutics for cancer im-munotherapy

On demand - Korea’s Rising Bio Stars On demand - New tools to conquerchronic kidney disease

SCHEDULEON DEMAND SESSIONS -





03:00 On demand - From research to mar-ket: developing a biotech project inWallonia

On demand - Health Equity: Address-ing Health Disparities During Thera-peutic Development

On demand - How COVID-19 is Bend-ing the Curve on Vaccine Develop-ment and Manufacturing Norms

On demand - Machine Learning (ML)methods for biomarker identificationfor microbiome therapeutics, diag-nostics and prognostics

On demand - How to develop im-munoregulatory pharmabiotics

04:00 On demand - Connecting clinic andcommercial: Biopharma manunfac-turing

On demand - Partnering in a pandem-ic world: in conversation with MartinCrook and Brian Cook

On demand - Expect more withSiegfried as your preferred partner

On demand - Using customizedphage cocktail mixture to eradicatebacteria in chronic diseases

On demand - Symbiotic Drugs: Phar-maceutical control of the gut micro-biome

05:00 On demand - Cross-Border Partneringbetween Europe, US & China

On demand - In conversation withJeetendra Vaghjiani

On demand - Designing scale up andmanufacturing processes for micro-biome therapeutics – end to endmanufacturing issues – manufactur-ing and analytical challenges

On demand - Commercialization op-portunities within the human micro-biome industry

06:00 On demand - Microbiome industrybreakthroughs – drug developmentplans

On demand - Linking immunity andcancer to human microbiome






07:00 On demand - Woman’s health careand vaginal microbiota

On demand - Strain-Level Profiling ofthe Gut Microbiome - A Novel Thera-peutic Strategy to Prevent or TreatSepsis

08:00 On demand - Building patent portfo-lios protecting microbiome therapeu-tics: Recent guidance and best strate-gies

On demand - Specializing and invest-ing in the microbiome spaces





Abologix

On demandNext Generation

Login and access partneringONE to watch therecording

Ab Studio, Inc.

On demandBiotech

Indication: Antibodies


Actimed Therapeutics

On demandScrip's 10 To Watch

Indication: Oncology


Chugai Pharmaceutical Co., Ltd.

On demandMidsize Pharma

View company profile and watch recording

Boehringer Ingelheim International GmbH

On demandLarge Pharma


Enable Therapeutics

On demandStartup Slam


BioWin/Wallonia Export - Investment Agency

On demandRegional Presentations


ImmTune Therapies



Accure Therapeutics SL



KyNexis Medicine Development AB



Accelerated Biosciences Corp.

On demandBiotech

Indication: Cell and Gene Therapies


Adaptate Biotherapeutics


Indication: Immuno-Oncology


Ildong Pharmaceutical



Johnson & Johnson Innovation



My Personal Therapeutics



Health Holland



Acthera Therapeutics AG



Pear Bio



Revibe Technologies



Arctoris



Agilex Biolabs

On demandBiotech

Indication: Drug Discovery and Development


Captor Therapeutics




Nippon Chemiphar



Merck KGaA



SESSIONSCOMPANY PRESENTATIONS -




https://informaconnect.com/bio-europe-virtual/
























SaNOtize Research and Development Corp

00:30 - 00:35Startup Slam


Swiss Biotech Association



Wildflower Biopharma, Inc.



Bioelectronica



Ajinomoto Co., Inc.

On demandBiotech



CellmAbs




Oasmia Pharmaceutical AB



MSD



BioStrand



bitBiome Inc



Akeso, Inc.

On demandBiotech



CytoSeek




Zambon



Novartis Pharma



Bowhead Health



amcure GmbH

On demandBiotech



Enesi Pharma Limited



Pfizer



Cognoptix



HaplnScience Inc.



Anima Biotech

On demandBiotech



Ikarovec






























Roche



Huen



Arecor Limited

On demandBiotech

Indication: Drug Delivery


Pneumagen


Indication: Infectious Diseases


Sanofi



LifeMatrix Technologies AG



MyLife Technologies B.V.



Atriva Therapeutics

On demandBiotech

Indication: Infectious Diseases


SOTIO




Servier



Neurix SA



Atrogi AB

On demandBiotech

Indication: Diabetes


TreeFrog Therapeutics




Pharmacorex



Rznomics Inc.



Aucentra Therapeutics

On demandBiotech



Teon Therapeutics, Inc.



Boehringer Ingelheim BiopharmaceuticalsGmbH

On demandBiotech

Indication: Contract Drug Development


Vertidiag



Wiregene



Boston Pharmaceuticals

On demandBiotech

Indication: Translational Drug Development



























CDR-Life

On demandBiotech

Indication:


Cellestia Biotech AG

On demandBiotech

Indication:


CENTOGENE GmbH

On demandBiotech

Indication: Rare and Orphan Diseases


Codexis

On demandBiotech



CohBar Inc.

On demandBiotech

Indication: Technologies and Tools


Daré Bioscience

On demandBiotech

Indication: Women's Health


DOMAIN THERAPEUTICS

On demandBiotech



Epsilogen Ltd

On demandBiotech



eTheRNA Immunotherapies NV

On demandBiotech



Eutilex

On demandBiotech



Faron Pharmaceuticals Ltd

On demandBiotech

Indication: Rare and Orphan Diseases


Helixmith Co., Ltd.

On demandBiotech



HepaRegeniX GmbH

On demandBiotech

Indication: Gastrointestinal


ILIAS Biologics

On demandBiotech



Immunecent Biotechnology

On demandBiotech

Indication: Autoimmune/Inflammation


Immutep Limited

On demandBiotech



InterAx Biotech

On demandBiotech

Indication:Drug Discovery and Development


Jaguar Health, Inc.

On demandBiotech

























Jubilant Therapeutics Inc

On demandBiotech



Juvabis AG

On demandBiotech


MD Healthcare Inc.

On demandBiotech

Indication: Microbiome


MedinCell

On demandBiotech

Indication: Drug Delivery


Neumentum, Inc.

On demandBiotech

Indication: Pain Management


Novago Therapeutics AG

On demandBiotech



Oculis S.A.

On demandBiotech

Indication: Ophthalmology


Orphagen Pharmaceuticals

On demandBiotech



OXURION NV

On demandBiotech

Indication: Ophthalmology


PEPperPRINT GmbH

On demandBiotech



RedHill Biopharma Ltd.

On demandBiotech



Refuge Biotech

On demandBiotech



RhoVac AB

On demandBiotech



Ryvu Therapeutics

On demandBiotech



Selvita

On demandBiotech



Shaperon

On demandBiotech

Indication: Autoimmune/Inflammation


Standigm Inc.

On demandBiotech



TargImmune Therapeutics

On demandBiotech



TOLLYS

On demandBiotech


























ULTIMOVACS ASA

On demandBiotech



VAXIMM AG

On demandBiotech



Vivoryon Therapeutics AG

On demandBiotech

Indication: CNS/Neurology


YSOPIA Bioscience (previously LNCTherapeutics)

On demandBiotech

Indication: Microbiome


ZeClinics

On demandBiotech












TIME BIOTECH LARGE PHARMA MIDSIZE PHARMA NEXT GENERATION REGIONAL PRESENTA-TIONS

SCRIP'S 10 TO WATCH STARTUP SLAM

00:00 On demand - Ab Studio,Inc.

On demand - AcceleratedBiosciences Corp.

On demand - Agilex Bio-labs

On demand - AjinomotoCo., Inc.

On demand - BoehringerIngelheim InternationalGmbH

On demand - Johnson &Johnson Innovation

On demand - Merck KGaA

On demand - MSD

On demand - ChugaiPharmaceutical Co., Ltd.

On demand - Ildong Phar-maceutical

On demand - NipponChemiphar

On demand - OasmiaPharmaceutical AB

On demand - Abologix

On demand - Accure Ther-apeutics SL

On demand - ActheraTherapeutics AG

On demand - Arctoris

On demand - Bioelectroni-ca

On demand - BioStrand

On demand - BioWin/Wal-lonia Export - InvestmentAgency

On demand - Health Hol-land

On demand - SwissBiotech Association

On demand - ActimedTherapeutics

On demand - AdaptateBiotherapeutics

On demand - Captor Ther-apeutics

On demand - CellmAbs

On demand - Enable Ther-apeutics

On demand - ImmTuneTherapies

On demand - KyNexisMedicine DevelopmentAB

On demand - My PersonalTherapeutics

On demand - Pear Bio

On demand - Revibe Tech-nologies

00:30 - SaNOtize Re-search and DevelopmentCorp

On demand - WildflowerBiopharma, Inc.

01:00 On demand - Akeso, Inc.

On demand - amcureGmbH

On demand - AnimaBiotech

On demand - Arecor Lim-ited

On demand - NovartisPharma

On demand - Pfizer

On demand - Roche

On demand - Sanofi

On demand - Zambon On demand - bitBiome Inc

On demand - BowheadHealth

On demand - Cognoptix

On demand - Hapln-Science Inc.

On demand - Huen

On demand - LifeMatrixTechnologies AG

On demand - CytoSeek

On demand - Enesi Phar-ma Limited

On demand - Ikarovec

On demand - Pneumagen

SCHEDULECOMPANY PRESENTATIONS -






02:00 On demand - Atriva Thera-peutics

On demand - Atrogi AB

On demand - AucentraTherapeutics

On demand - BoehringerIngelheim Biopharmaceu-ticals GmbH

On demand - Servier On demand - MyLife Tech-nologies B.V.

On demand - Neurix SA

On demand - Pharma-corex

On demand - RznomicsInc.

On demand - Teon Thera-peutics, Inc.

On demand - Vertidiag

On demand - SOTIO

On demand - TreeFrogTherapeutics

03:00 On demand - BostonPharmaceuticals

On demand - CDR-Life

On demand - CellestiaBiotech AG

On demand - CENTO-GENE GmbH

On demand - Wiregene

04:00 On demand - Codexis

On demand - CohBar Inc.

On demand - Daré Bio-science

On demand - DOMAINTHERAPEUTICS







05:00 On demand - EpsilogenLtd

On demand - eTheRNAImmunotherapies NV

On demand - Eutilex

On demand - Faron Phar-maceuticals Ltd

06:00 On demand - HelixmithCo., Ltd.

On demand - HepaRe-geniX GmbH

On demand - ILIAS Biolog-ics

On demand - ImmunecentBiotechnology

07:00 On demand - ImmutepLimited

On demand - InterAxBiotech

On demand - JaguarHealth, Inc.

On demand - JubilantTherapeutics Inc







08:00 On demand - Juvabis AG

On demand - MD Health-care Inc.

On demand - MedinCell

On demand - Neumen-tum, Inc.

09:00 On demand - NovagoTherapeutics AG

On demand - Oculis S.A.

On demand - OrphagenPharmaceuticals

On demand - OXURIONNV

10:00 On demand - PEPper-PRINT GmbH

On demand - RedHill Bio-pharma Ltd.

On demand - RefugeBiotech

On demand - RhoVac AB

11:00 On demand - Ryvu Thera-peutics

On demand - Selvita

On demand - Shaperon

On demand - StandigmInc.







12:00 On demand - TargImmuneTherapeutics

On demand - TOLLYS

On demand - ULTI-MOVACS ASA

On demand - VAXIMM AG

13:00 On demand - VivoryonTherapeutics AG

On demand - YSOPIA Bio-science (previously LNCTherapeutics)

On demand - ZeClinics





EIT Health Innostars Awards Grand Final

14:30 - 17:00Additional Program

Join us at the InnoStars Awards Grand Final pitchingcontest with Europe’s 10 best promising healthcarestartups in 2020! During InnoStars Awards Grand Final,you will have the opportunity to meet the 10 finalists ofEIT Health InnoStars Awards 2020 through pitches and1:1 sessions.

About the InnoStars Awards program

InnoStars Awards helps start-ups from progressiveEuropean regions to validate their healthcareinnovations, attract investors and ultimately shortenthe time to get business ideas to the market. Theprogram is open for micro and small enterprises, spin-offs and start-ups that already have a prototype or aMinimum Viable Product (MVP). All selected start-upsreceive €25 000 smart money, individual mentoring forsix months and the opportunity to participate in twobootcamps in Europe. After the four-month program,ten finalists are selected to participate in the InnoStarsAwards final pitch contest in October, to compete forthe three top prizes: an additional €25 000, €15 000 or€10 000 in funding. Beyond this, the start-ups haveaccess to the support and potential investorconnections available from EIT Health’s InvestorNetwork and EIT Health’s Living Labs and Test Bedsnetwork.

Participants

Judge: Adam Broncel - General Partner, BiomedInnovation VC Fund

Judge: Filipa Fixe - Executive Board Member, Glintt

Judge: Ilona Kecskés - CEO, Capital Community

Presenter: Ana Maria Onica - Co-founder and CEO,Voxikids

Presenter: Madalin Margan - CEO, Oncochain

Presenter: Monica Piergiovanni - CEO, mEryLo'

Presenter: Andras Szilagyi - CEO, IT MEDicine

Presenter: Daniel Barbu - CEO, I'm Fine

Presenter: Robert Ackermann - CCO, Phoenix Orthosis

Presenter: Veronika Hudzikova - CEO, INOVUJ FaceRebab

Presenter: Gatis Mozoleskis - Co-founder, CellboxLabs

Presenter: Zajzon Bodó - CEO, Babyndex

Presenter: Dovydas Matuliauskas - CFO, Ligence

Presenter: Celso Almeida - CEo, Endobios

BIO-Europe Digital 2020 Networking: Long-lasting partnerships are like happy marriages

17:00 - 17:30Networking

Fully Booked!!

Signing a deal with another company oftentimes feelslike a wedding celebration. For months or years youare preparing, discussing every aspect, and are full ofexcitement when signatures are finally beingexchanged. But then, the real work actually begins.As with every marriage, partnerships between twocompanies go through similar ups and downs over theyears and no marriage or partnership is like another.Hence, there is also no secret recipe but experienceshows that there are a few learnings that can beapplied more broadly to ensure a partnership is asfruitful and lasting like a happy marriage.

Join our networking event to further build newconnections and exchange tips on managing lastingpartnerships, especially now in a fully virtual set-up.We look forward to your participation.

To give the virtual event the feeling of a realnetworking session, we encourage you to bring yourown beverage!

Participants

Speaker: Urs Schleuniger - Global Head Alliance &Asset Management, Roche Pharma Partnering

Innovating the partnering future

17:30 - 18:30Plenary

The coronavirus pandemic has resulted in innovationand collaboration round the globe at an unprecedentedspeed. In what other ways can innovation besupported in a crisis? Are there particular partneringmodels and collaboration frameworks that cansupport innovation across borders to meet universalunmet medical needs? What role do public privatepartnerships play in answering major global healthcarechallenges? The plenary session at BIO-Europe willbring together participants in current collaborations toidentify future directions for ecosystem innovation.

Participants

Moderator: Luke Timmerman - Founder and Editor,Timmerman Report

Panelist: Marianne De Backer - Member ofPharmaceuticals Executive Committee and ExecutiveVP and Head of Strategy, Business Development &Licensing, Bayer AG

Panelist: J. Joseph Kim - President, CEO, Director,Inovio Pharmaceuticals

Panelist: Melanie Saville - Director, Vaccine Researchand Development, CEPI (Coalition for EpidemicPreparedness Innovations)

Panelist: Paul Stoffels - Executive Vice President,Chief Scientific Officer, Johnson & Johnson

BIO-Europe Digital 2020 Networking:Introducing the 24/7 Café

On demandNetworking

The #newnormal provides us with a range of newopportunities.

We are introducing the truly global 24/7 Café. Thisinitiative provides a serendipitous way to meet otherconference delegates, it’s open 24/7 and is a place togo to whenever you have time for a break.

Check-in to see if someone, somewhere else on thisplanet had just the same thought as you and is takinga break at the same time!

Take advantage of this informal mingling!

Log into partneringONE to access the 24/7 café onyour Agenda.

SESSIONSDAY 1 - LIVE SESSIONS - 26/10/2020




TIME ADDITIONAL PROGRAM NETWORKING PLENARY

14:00 14:30 - EIT Health Innostars AwardsGrand Final

15:00

16:00

17:00 17:00 - BIO-Europe Digital 2020 Network-ing: Long-lasting partnerships are likehappy marriages

On demand - BIO-Europe Digital 2020Networking: Introducing the 24/7 Café

17:30 - Innovating the partnering future

SCHEDULEDAY 1 - LIVE SESSIONS - 26/10/2020




Innovative medical products – gene therapyand beyond

12:30 - 13:00Spotlight

Participants

Moderator: Horst Domdey - Managing Director, BioM

What has COVID taught us so far?


Participants

Introduction: Katharina Gräfe - Scientific Officer,BIO.NRW

Moderator: Bernward Garthoff - CEO, BIOClustermanagement NRW

Panelist: Thomas Schweins - Senior VP, Life ScienceBusiness Area, Qiagen

Panelist: Stephan Wnendt - CEO, MLM Medical Labs

Panelist: Holger Zimmermann - CEO, AiCuris

Panelist: Karl Ziegelbauer - Head of Open Innovationand Digital Tech, Bayer

Startup Slam


This exciting competition offers entrepreneurs achance to virtually pitch their company at BIO-EuropeDigital 2020. Selected companies will have theopportunity to create a five-minute video pitch, whichwill be hosted on the digital event site, and participatein a live feedback session. A jury of leading investors,pharma dealmakers and biotech business key opinionleaders will evaluate the pitches and select the winnerduring the live session. Learn more here.

Participants

Moderator: Madelaine Holden - Innovation ActivationSenior Manager EMEA, Johnson & Johnson Innovation

Judge: Juliette Audet - Principal, Forbion

Judge: Leonildo Delgado - Manager, Innovation andSourcing, BaseLaunch

Judge: Simon Kerry - Operating Partner, Advent LifeSciences

Judge: Elena Fernandez-Kleinlein - Head of JLABSEMEA, Johnson & Johnson Innovation

Judge: Sunil Shah - CEO, o2h Group


On demandNetworking






BiotechBikers Live Ride and Networking Hour


Attention Peloton #BiotechBikers! Together withMorrie Ruffin, Martina Molsbergen and Ian Wisenberg,EBD's Anna Chrisman will be hosting the first ever#BiotechBikers Live Ride and Networking Hour duringBIO-Europe next week!

Update: The live class was cancelled, therefore we’veselected an on demand class and tried to find aplaylist that resembled our usual Tuesday night danceparty at BIO-Europe.

Instructions:

• In your Peloton Profile, select the tag#BiotechBikers and set your location to BIO-Europe

• UPDATED: Select the class (search for Leanne’s90s ride from 7/7/20 or bookmarkhttps://members.onepeloton.com/classes/cycling?utm_source=ios_app&utm_medium=in_app&modal=classDetailsModal&classId=ee787068c1f446bfbdb1e8f52460daa1)

• Show up: Tuesday Oct 27 at 18:30 CET/1.30 PMEastern, select the “here now” view and press startexactly at the 1:30 PM Eastern.

• Ride, sweat and let the High Fives fly!

At 19.10 CET/14.10 Eastern, join the ''watercoolernetworking session'' in the BIO-Europe Virtual Hub. Notime to shower - we're keeping it real! Brag about yourPRs, gossip about our favorite instructors and maybeeven set up future group rides.





https://informaconnect.com/bioeurope/startup-slam/

TIME NETWORKING SPOTLIGHT

12:00 12:30 - Innovative medical products – gene therapy and beyond

13:00

14:00 14:00 - What has COVID taught us so far?

15:00 15:00 - Startup Slam

16:00

17:00 On demand - BIO-Europe Digital 2020 Networking: Introducingthe 24/7 Café

18:00 18:30 - BiotechBikers Live Ride and Networking Hour





#BiotechBiker Zwift Ride


Want another chance to meet up with the#BiotechBiker community? Join us for a virtual sunriseZwift group ride in France!

Here's how to join:

Before:

• Follow ride leader Mark Farmery on the ZwiftCompanion App (zwift.com)

• You’ll receive an invitation for the BIO-Europe 2020Zwift Meetup, accept and you’re all set

On the day:

• Log in to Zwift, follow the Meetup instructions, fillyour bidon and be ready on Wednesday October28th at 06.00 CET for 45 min ride at an easy paceon the Roule Ma Poule course in France

Ride on!

EIT Health Headstart : COVID-19 focus


The EIT Health Headstart brings together top-tier start-ups addressing significant health challenges facingEurope today. Join the virtual Grand Final of this well-known competition and meet 15 specially selectedteams who are developing revolutionary healthcareproducts and solutions. They will compete for the poolprize, which is 80 000 €.

EIT Health’s Headstart Programme accelerates themarket launch of selected healthcare start-upsthrough grants as well as support with networking anddeveloping a project plan. Mentored by EIT Health’sregional teams, the programme offers support to thecompanies as they navigate the steps required to bringtheir solution to market including, crucially, verificationof the clinical, patient or system need for the productor service.

The Top 15 start-ups that have reached the Finals arefrom Southern, Central and Eastern Europe. The teamshave developed products and services in areas suchas cancer, geriatrics, ophthalmology, wound care,women’s health, genetic and neurological conditions,cardiology and digital tools to assist healthcareservices in the management of patients as well asresearch and development.

This year, Headstart is supplemented by two specialprogrammes, COVID-19 and NAM.

COVID-19 Cohort

In 2020, EIT Health expanded the scope of Headstartto assist in the immediate need for solutions tocombat COVID-19, and has selected a specific groupof start-ups that will develop products and servicesthat will help Europe to contain, treat and manage thedisease.

More: https://eithealth.eu/project/headstart/

Participants

Presenter: Giordano Botta - CEO, Allelica

Presenter: Vasileia Chatzistergiou - Co-founder,Medical Data and Communication Manager, BookingClinic

Presenter: Giuseppe Cordella - Founder and CEO,Drivesec

Presenter: Sergey Jakimov - Co-founder and CEO,Longenesis

Fireside chat screening with President ofNovartis Institute of Biomedical Research(NIBR) and Live Q&A with Novartis Partnering


Join Nigel Sheail, Global Head Mergers andAcquisitions and Business Development and Licensingfor a screening of the On Demand fireside chat withJames Bradner, President of the Novartis Institutes forBioMedical Research, followed by a live Q&A, whereNigel will answer questions from the audience.

Participants

Host: Nigel Sheail - Global Head, Mergers &Acquisitions and Business Development & Licensing,Novartis

A Day in the life of experienced dealmakers

16:00 - 17:00Plenary

Participants

Moderator: Evonne Sepsis - Founder and ManagingDirector, ESC Advisors

Moderator: Anton Gueth - Managing Director,EVOLUTION Life Science Partners

Panelist: Marc de Garidel - Chairman, Ipsen

Panelist: Stelios Papadopoulos - Chairman of theBoard, Biogen, Exelixis, Regulus Therapeutics

Panelist: James Sabry - Global Head, PharmaPartnering, Roche

Live Q&A with AGC


Participants

Host: Luca Alberici , AGC Biologics

Host: Bryson Kneller - VP Process Development, AGCBiologics





https://zwift.com/

https://eithealth.eu/project/headstart/


In conversation with Philippe Lopes-Fernandes, Executive Vice President and CBO,IPSEN

17:30 - 18:15Plenary

Join this live chat between Anna Chrisman, PresidentInforma Connect Life Sciences and Philippe Lopes-Fernandes, Executive Vice President and CBO, IPSEN.

As communities around the world continue to work tocontrol the spread of COVID-19 and keep people safe,we are confronted with the need to find new ways tocome together to advance our pipelines and delivertransformational therapies to patients. Major businessdevelopment and partnering meetings will continue tobe virtual into 2021, and it is increasingly likely that thevirtual world will continue beyond 2021 and evenCOVID. Philippe Lopes-Fernandes has always beenwilling to think differently about BD and try newapproaches to making connections. He did thisrecently on a personal level, changing companies inthe middle of the pandemic. Now the Executive VicePresident and Chief Business Officer of Ipsen, Philippewill join us from his home office to talk about virtualdeal making, transitioning jobs during a pandemic andhis thoughts on what type of deals to expect from theindustry in 2021.

Stay on for a lively networking session immediatelyfollowing to chat with Anna and Philippe about Covid,its impact on our lives, #biotechbikers or#biotechrunners and whatever else comes to mind.

Participants

Guest: Philippe Lopes-Fernandes - Executive VicePresident and CBO, IPSEN

Host: Anna Chrisman - Managing Director Pharma andLife Sciences, Informa Connect


On demandNetworking











06:00 06:00 - #BiotechBiker Zwift Ride

07:00

08:00

09:00

10:00

11:00

12:00

13:00

14:00 14:00 - EIT Health Headstart : COVID-19focus

15:00 15:00 - Fireside chat screening with Pres-ident of Novartis Institute of BiomedicalResearch (NIBR) and Live Q&A with No-vartis Partnering

16:00 16:00 - A Day in the life of experienceddealmakers

17:00 17:00 - Live Q&A with AGC

On demand - BIO-Europe Digital 2020Networking: Introducing the 24/7 Café

17:30 - In conversation with PhilippeLopes-Fernandes, Executive Vice Presi-dent and CBO, IPSEN






On demandNetworking






BIO-Europe Digital 2020 Networking: Long-lasting partnerships are like happy marriages


Fully Booked!

Signing a deal with another company oftentimes feelslike a wedding celebration. For months or years youare preparing, discussing every aspect, and are full ofexcitement when signatures are finally beingexchanged. But then, the real work actually begins.Aswith every marriage, partnerships between twocompanies go through similar ups and downs over theyears and no marriage or partnership is like another.Hence, there is also no secret recipe but experienceshows that there are a few learnings that can beapplied more broadly to ensure a partnership is asfruitful and lasting like a happy marriage.Join our networking event to further build newconnections and exchange tips on managing lastingpartnerships, especially now in a fully virtual set-up.We look forward to your participation.To give the virtual event the feeling of a realnetworking session, we encourage you to bring yourown beverage!

Fully Booked!

Participants

Speaker: Urs Schleuniger - Global Head Alliance &Asset Management, Roche Pharma Partnering

EIT Health Headstart : Cohort A


The EIT Health Headstart brings together top-tier start-ups addressing significant health challenges facingEurope today. Join the virtual Grand Final of this well-known competition and meet 15 specially selectedteams who are developing revolutionary healthcareproducts and solutions. They will compete for the poolprize, which is 80 000 €.EIT Health’s Headstart Programme accelerates themarket launch of selected healthcare start-upsthrough grants as well as support with networking anddeveloping a project plan. Mentored by EIT Health’sregional teams, the programme offers support to thecompanies as they navigate the steps required to bringtheir solution to market including, crucially, verificationof the clinical, patient or system need for the productor service.The Top 15 start-ups that have reached the Finals arefrom Southern, Central and Eastern Europe. The teamshave developed products and services in areas suchas cancer, geriatrics, ophthalmology, wound care,women’s health, genetic and neurological conditions,cardiology and digital tools to assist healthcareservices in the management of patients as well asresearch and development.

This year, Headstart is supplemented by two specialprogrammes, COVID-19 and NAM.More: https://eithealth.eu/project/headstart/

Participants

Presenter: Sebastião van Uden - CEO, Bac3Gel

Presenter: Sara Lobo - Co-founder and CMO, C-moMedical Solutions

Presenter: Cornel Amariei - Founder, DOTLUMEN

Presenter: Massimiliano Clamer - Founder andPresident, IMMAGINA BioTechnology

Presenter: Alfonso Maria Ponsiglione - Co-founderand COO, Kyme NanoImaging

Presenter: David Breitenbach - Co-founder, SinekoGlobal

Presenter: Ivan Porro - Founder and CEO, SurgiQ

Presenter: Daniele Conti - Co-founder and CEO,SYNDIAG

EIT Health Headstart : Cohort B


The EIT Health Headstart brings together top-tier start-ups addressing significant health challenges facingEurope today. Join the virtual Grand Final of this well-known competition and meet 15 specially selectedteams who are developing revolutionary healthcareproducts and solutions. They will compete for the poolprize, which is 80 000 €.

EIT Health’s Headstart Programme accelerates themarket launch of selected healthcare start-upsthrough grants as well as support with networking anddeveloping a project plan. Mentored by EIT Health’sregional teams, the programme offers support to thecompanies as they navigate the steps required to bringtheir solution to market including, crucially, verificationof the clinical, patient or system need for the productor service.

The Top 15 start-ups that have reached the Finals arefrom Southern, Central and Eastern Europe. The teamshave developed products and services in areas suchas cancer, geriatrics, ophthalmology, wound care,women’s health, genetic and neurological conditions,cardiology and digital tools to assist healthcareservices in the management of patients as well asresearch and development.

This year, Headstart is supplemented by two specialprogrammes, COVID-19 and NAM.

NAM Healthy Longevity Global Competition

In 2020, Headstart offers an added opportunity forventures with a focus on physical, mental, and socialwell-being for people as they age, joining the U.S. NAMHealthy Longevity Global Competition. TheCompetition includes a three-tiered structure ofawards: a first phase of Catalyst Awards, a secondphase of Accelerator Award, and a third Grand Prizephase. Through Headstart, EIT Health holds a CatalystAward competition, participating in the first phase ofthe Global Competition.

More: https://eithealth.eu/project/headstart/

Participants

Presenter: Eugene Nayshtetik - Founder andManaging Partner, Lorton Investments - SenceBand

Presenter: Katarzyna Zimoląg - CEO, i-Care

Presenter: Riccardo Piccioli - Co-founder and CEO,Mysurable









COVID-19 therapeutics: Modality, efficacy andimplications for access

17:00 - 18:00Plenary

As COVID-19 infections spread around the world,companies moved swiftly to test many of the productsin their pipelines. This has led to a broad array of novelapproaches to treating patients infected with the virus,from antibodies that could be given as prevention totreatments that help reduce the impact of the cytokinestorm or Acute Respiratory Distress Syndrome (ARDS).This panel of top scientists and industry leaders willshare information on the development of these non-vaccine treatment options and address the challengesaround achieving global access to these products.The session will also feature an update on the

landscape of therapeutics and vaccines indevelopment for COVID-19.

Participants

Moderator: Phyllis Arthur - VP, Infectious Disease andVaccine Policy, Biotechnology Innovation Organization(BIO)

Speaker: David Thomas - VP, Industry Research andAnalysis, Biotechnology Industry Organization (BIO)

Panelist: Richard Marsden - CEO, Synairgen

Panelist: Neil Mulcock - VP, Government Affairs,EMEA, Gilead Sciences

Panelist: Kylie O'Keefe - VP, Global CommercialStrategy, PTC Therapeutics

Panelist: Gregg Szabo - VP and Commercial Leader,Virology/Immunology, MSD






09:00 On demand - BIO-Europe Digital 2020Networking: Introducing the 24/7 Café

10:00 10:00 - BIO-Europe Digital 2020 Network-ing: Long-lasting partnerships are likehappy marriages

11:00 11:00 - EIT Health Headstart : Cohort A

12:00

13:00

14:00

15:00 15:30 - EIT Health Headstart : Cohort B

16:00

17:00 17:00 - COVID-19 therapeutics: Modality,efficacy and implications for access





sessions bio-europe...panelist: regina hodits - managing partner, wellington partners life sciences...

Documents